+

WO2006053063A3 - Dosage de notch-1 utilise dans la detection de maladies neurodegeneratives - Google Patents

Dosage de notch-1 utilise dans la detection de maladies neurodegeneratives Download PDF

Info

Publication number
WO2006053063A3
WO2006053063A3 PCT/US2005/040625 US2005040625W WO2006053063A3 WO 2006053063 A3 WO2006053063 A3 WO 2006053063A3 US 2005040625 W US2005040625 W US 2005040625W WO 2006053063 A3 WO2006053063 A3 WO 2006053063A3
Authority
WO
WIPO (PCT)
Prior art keywords
notch
assay
nicd
levels
neurodegenerative diseases
Prior art date
Application number
PCT/US2005/040625
Other languages
English (en)
Other versions
WO2006053063A2 (fr
Inventor
Stanley B Prusiner
Stephen J Dearmond
Original Assignee
Univ California
Stanley B Prusiner
Stephen J Dearmond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Stanley B Prusiner, Stephen J Dearmond filed Critical Univ California
Publication of WO2006053063A2 publication Critical patent/WO2006053063A2/fr
Publication of WO2006053063A3 publication Critical patent/WO2006053063A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un dosage permettant de déterminer les niveaux de Notch-1 dans un échantillon. Une augmentation des niveaux de Notch-1 au-delà des niveaux normaux est associée à une plus grande probabilité de la présence d'une maladie neurodégénérative. Le domaine intracellulaire de Notch-1 (NICD) peut être détecté à l'aide d'un anticorps spécifique au NICD. Un anticorps étiqueté permet de visualiser la quantité et le modèle de distribution du NICD qui est comparé à un témoin normal pour indiquer la présence d'une maladie neurodégénérative, y compris la maladie de Creutzfeldt-Jakob (CJD).
PCT/US2005/040625 2004-11-05 2005-11-02 Dosage de notch-1 utilise dans la detection de maladies neurodegeneratives WO2006053063A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62548604P 2004-11-05 2004-11-05
US60/625,486 2004-11-05

Publications (2)

Publication Number Publication Date
WO2006053063A2 WO2006053063A2 (fr) 2006-05-18
WO2006053063A3 true WO2006053063A3 (fr) 2007-05-03

Family

ID=36337189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/040625 WO2006053063A2 (fr) 2004-11-05 2005-11-02 Dosage de notch-1 utilise dans la detection de maladies neurodegeneratives

Country Status (1)

Country Link
WO (1) WO2006053063A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
CN101563366B (zh) 2006-10-19 2012-10-03 健泰科生物技术公司 抗notch3激动性抗体及其在制备治疗notch3相关疾病的药物中的用途
US7994285B2 (en) 2006-10-19 2011-08-09 Genentech, Inc. Anti-Notch3 antibodies
EP2099827B1 (fr) 2006-12-18 2018-11-21 Genentech, Inc. Anticorps anti-notch3 antagonistes et utilisations de ces derniers dans la prophylaxie et le traitement de maladies liées à notch3
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
MY159815A (en) 2008-07-08 2017-02-15 Oncomed Pharm Inc Notch1 receptor binding agents and methods of use thereof
JP5710487B2 (ja) 2008-10-01 2015-04-30 ジェネンテック， インコーポレイテッド 抗ｎｏｔｃｈ２抗体および使用方法
EP2443151A1 (fr) 2009-06-18 2012-04-25 Pfizer Inc. Anticorps anti-notch-1
KR20150088334A (ko) 2010-12-15 2015-07-31 와이어쓰 엘엘씨 항-노치1 항체
TW201726746A (zh) 2012-11-07 2017-08-01 輝瑞股份有限公司 抗切口３（ａｎｔｉ-ｎｏｔｃｈ３）抗體及抗體-藥物共軛體

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEREZOVSKA ET AL.: "Notch1 Inhibits Neurite Outgrowth in Postmitotic Primary Neurons", NEUROSCIENCE, vol. 93, no. 2, 1999, pages 433 - 439 *
REDMOND ET AL.: "Nuclear Notch 1 signaling and the regulation of dendritic development", NATURE NEUROSCIENCE, vol. 3, no. 1, January 2000 (2000-01-01), pages 30 - 40, XP003012721 *
SESTAN ET AL.: "Contact-Dependent Inhibition of Cortical Neurite Growth Mediated by Notch Signaling", SCIENCE, vol. 286, 22 October 1999 (1999-10-22), pages 741 - 746, XP003012722 *
YU ET AL.: "Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing", NATURE, vol. 407, 7 September 2000 (2000-09-07), pages 48 - 54, XP002173751 *

Also Published As

Publication number Publication date
WO2006053063A2 (fr) 2006-05-18

Similar Documents

Publication Publication Date Title
WO2006053063A3 (fr) Dosage de notch-1 utilise dans la detection de maladies neurodegeneratives
WO2005057166A3 (fr) Detection de proteines et de prions alteres de maniere conformationnelle
WO2007009047A3 (fr) Substrats, detecteurs et methodes servant a evaluer des etats chez la femelle
USD623303S1 (en) Analytical test interpretation card
WO2006091734A3 (fr) Compositions et procedes de classification d'echantillons biologiques
WO2008106648A3 (fr) Immunoessais présentant une réduction dans des phénomères de prozone
TW200636245A (en) Colorimetric sensors constructed of diacetylene materials
WO2006084130A3 (fr) Systemes de detection ultrasensible utilisant des signaux multidimensionnels
WO2010061283A8 (fr) Biomarqueurs pour diagnostiquer et détecter la progression de troubles neurodégénératifs, en particulier de la sclérose latérale amyotrophique
WO2011072177A3 (fr) Dosage de biomarqueurs pour le diagnostic et le classement des maladies cardiovasculaires
WO2008148072A3 (fr) Variations genetiques liees a une maladies et methodes de detection et d'utilisation de ces variations
WO2007053480A3 (fr) Proteine demethylase a domaine jmjc
WO2010021822A3 (fr) Découverte de biomarqueurs candidats d’apoptose in vivo par profilage global de sites de coupure de caspase
WO2007114986A3 (fr) Sondes coopératives et leurs procédés d'utilisation
WO2010045490A3 (fr) Mappage sur hyperespace multidimensionnel de biomarqueur humain pour des troubles dépressifs
WO2009055218A3 (fr) Inspection non destructive d'une structure comprenant l'analyse de la réponse à un champ électromagnétique d'une cavité
WO2008073425A3 (fr) Dosage grande sensibilité de la protéolyse
WO2009143098A3 (fr) Auto-anticorps humains isolés dirigés contre des peptides natriurétiques et procédés et kits pour détecter des auto-anticorps humains dirigés contre des peptides natriurétiques
WO2006069023A3 (fr) Procede et appareil d'analyse avec effets de matrices d'echantillons reduits
WO2008117027A3 (fr) Procédé
WO2008155891A1 (fr) Nouveau marqueur d'une maladie artériosclérotique
WO2005118836A3 (fr) Essai d'activite de prolyl hydroxylase de hif
WO2008131261A3 (fr) Biomarqueurs peptidiques de maladie cardiovasculaire
EP2312313A3 (fr) Sondes immobilisées et methodes de détection de protéines prions modifiées de maniére conformationnelle
WO2006110748A3 (fr) Gene de reponse au complement 32 (rgc-32) lors d'une maladie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05848784

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载